HC Wainwright reiterated their buy rating on shares of Alimera Sciences, Inc. (NASDAQ:ALIM) in a report released on Wednesday morning. The brokerage currently has a $5.00 target price on the biopharmaceutical company’s stock.
A number of other research firms have also weighed in on ALIM. ValuEngine lowered Alimera Sciences from a sell rating to a strong sell rating in a research note on Monday, September 18th. Zacks Investment Research lowered Alimera Sciences from a hold rating to a sell rating in a research note on Thursday, August 17th. Finally, Cowen Inc reaffirmed a buy rating on shares of Alimera Sciences in a research note on Thursday, November 2nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. Alimera Sciences currently has a consensus rating of Hold and an average price target of $3.38.
Shares of Alimera Sciences (NASDAQ ALIM) opened at $1.26 on Wednesday. Alimera Sciences has a 52 week low of $1.04 and a 52 week high of $1.72. The company has a current ratio of 4.84, a quick ratio of 4.65 and a debt-to-equity ratio of -0.71.
Institutional investors and hedge funds have recently bought and sold shares of the business. KCG Holdings Inc. raised its holdings in Alimera Sciences by 127.0% in the first quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 43,977 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in Alimera Sciences by 24.3% in the second quarter. PNC Financial Services Group Inc. now owns 180,300 shares of the biopharmaceutical company’s stock worth $251,000 after purchasing an additional 35,200 shares in the last quarter. Stonepine Capital Management LLC raised its holdings in Alimera Sciences by 158.2% in the third quarter. Stonepine Capital Management LLC now owns 477,226 shares of the biopharmaceutical company’s stock worth $644,000 after purchasing an additional 292,399 shares in the last quarter. Finally, JW Asset Management LLC raised its holdings in Alimera Sciences by 15.6% in the second quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock worth $1,343,000 after purchasing an additional 130,000 shares in the last quarter. Institutional investors and hedge funds own 37.33% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece was posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://transcriptdaily.com/2017/11/26/alimera-sciences-alim-buy-rating-reaffirmed-at-hc-wainwright.html.
About Alimera Sciences
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.